- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07687459
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.
The purpose of this study is to evaluate if Rentosertib (INS018_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018_055).
In this study, Rentosertib (INS018_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018_055) works to treat Idiopathic Pulmonary Fibrosis.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Qinhan Chen
- Telefoonnummer: +86 021-50831718
- E-mail: Insilico-Clinicaltrial@insilico.ai
Studie Locaties
-
-
Anhui
-
Hefei, Anhui, China
- Nog niet aan het werven
- Anhui Provincial Hospital
-
Hefei, Anhui, China
- Nog niet aan het werven
- Anhui Chest Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Werving
- Peking Union Medical College Hospital
-
Beijing, Beijing Municipality, China
- Werving
- Beijing Friendship hospital, Capital Medical University
-
Beijing, Beijing Municipality, China
- Nog niet aan het werven
- Beijing Chaoyang Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, China
- Nog niet aan het werven
- Fuzhou University Affiliated Provincial Hospital
-
Xiamen, Fujian, China
- Werving
- The Second Affiliated Hospital of Xiamen Medical College
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Werving
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Guangdong, China
- Nog niet aan het werven
- Nanfang Hospital, Southern Medical University
-
-
Guangxi
-
Nanning, Guangxi, China
- Nog niet aan het werven
- The First Affiliated Hospital of Guangxi Medical University
-
-
Hainan
-
Haikou, Hainan, China
- Werving
- Hainan General Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China
- Nog niet aan het werven
- The Second Hospital of Hebei Medical University
-
Shijiazhuang, Hebei, China
- Nog niet aan het werven
- Hebei Medical University Third Hospital
-
-
Henan
-
Anyang, Henan, China
- Werving
- The People's Hospital of Anyang City
-
Nanyang, Henan, China
- Werving
- Nanyang First People's Hospital
-
Zhengzhou, Henan, China
- Nog niet aan het werven
- Henan Provincial People's Hospital
-
Zhengzhou, Henan, China
- Nog niet aan het werven
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan, Hubei, China
- Nog niet aan het werven
- Renmin Hospital of Wuhan University
-
Wuhan, Hubei, China
- Nog niet aan het werven
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Yichang, Hubei, China
- Nog niet aan het werven
- Yichang Central People's Hospital
-
-
Hunan
-
Changsha, Hunan, China
- Nog niet aan het werven
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, China
- Nog niet aan het werven
- The Xiangya Hospital of Central South University
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, China
- Nog niet aan het werven
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Werving
- Nanjing Drum Tower Hospital
-
Xuzhou, Jiangsu, China
- Nog niet aan het werven
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- Nog niet aan het werven
- Jiangxi Provincial People' Hospital
-
-
Jilin
-
Changchun, Jilin, China
- Nog niet aan het werven
- The Second Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, China
- Nog niet aan het werven
- Shengjing Hospital of China Medical University
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- Werving
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Xi'an, Shaanxi, China
- Werving
- The First Affiliated Hospital of Xi'an Medical College
-
-
Shandong
-
Jinan, Shandong, China
- Nog niet aan het werven
- Qilu Hospital of Shandong University
-
Jinan, Shandong, China
- Nog niet aan het werven
- Introduction of the First Affiliated Hospital of Shandong First Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Werving
- Shanghai Pulmonary Hospital Affiliated to Tongji University
-
-
Shanxi
-
Taiyuan, Shanxi, China
- Nog niet aan het werven
- Shanxi Bethune Hospital
-
Yuncheng, Shanxi, China
- Nog niet aan het werven
- Yuncheng Central Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China
- Nog niet aan het werven
- West China Hospital, Sichuan University
-
Chengdu, Sichuan, China
- Nog niet aan het werven
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China
- Nog niet aan het werven
- Tianjin Medical University General Hospital
-
Tianjin, Tianjin Municipality, China
- Nog niet aan het werven
- Tianjin Chest Hospital
-
-
Xinjiang
-
Ürümqi, Xinjiang, China
- Nog niet aan het werven
- The First Affiliated Hospital of Xinjiang Medical University
-
-
Yunnan
-
Kunming, Yunnan, China
- Nog niet aan het werven
- The First People Hospital of Yunnan Province
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Nog niet aan het werven
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, China
- Werving
- Affiliated Hangzhou First People's Hospital,School of Medicine, Westlake University
-
Jiaxing, Zhejiang, China
- Nog niet aan het werven
- The First Hospital of Jiaxing
-
Ningbo, Zhejiang, China
- Nog niet aan het werven
- Ningbo Medical Center Lihuili Hospital
-
Ningbo, Zhejiang, China
- Nog niet aan het werven
- The First Affiliated Hospital of Ningbo University
-
Wenzhou, Zhejiang, China
- Nog niet aan het werven
- The First Affiliated Hospital of Wenzhou Medical University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- An informed consent form (ICF) signed and dated at screening (Visit 1), prior to initiation of any study related procedures, and in accordance with ICH-GCP and local legislation.
- Patients aged ≥40 years at time of signing the ICF.
- Diagnosis of IPF based on the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline, confirmed by an HRCT chest scan within 3 months prior to screening visit.
- UIP or probable UIP with fibrosis extent >10% at HRCT.
Meet all the following criteria during the screening period:
- FVC ≥45% predicted of normal
- FEV1/FVC ≥0.7
- DLCO (corrected for hemoglobin) ≥25% and <80% predicted of normal.
Background antifibrotic therapies are allowed, patients may be either:
- on a stable therapy with nintedanib or pirfenidone as monotherapy for at least 12 weeks prior to screening visit and during the screening period and are planning to stay on this background treatment after randomization.
- not on a treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening visit and during the screening period and do not plan to start or restart antifibrotic therapy.
- Estimated minimum life expectancy of at least 30 months for non-IPF related disease in the opinion of the investigator.
- Male patients and female patients of childbearing potential agree to use highly effective contraception/preventive exposure measures from the time of the first dose of the study drug (for the male patient) or the signing of the ICF (for the female patient) until 90 days after the last dose of the study drug.
Exclusion criteria:
- Interstitial lung disease associated with known primary diseases (eg, autoimmune disease-related interstitial lung diseases, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos, and coal dust), or drugs (eg, amiodarone).
- Previous participation in a clinical study with rentosertib (active or placebo).
- Concurrent participation in another interventional drug, device, or biological investigational research study, or use of an investigational agent within 5 half-lives of the agent (or within 8 weeks when half-life is unknown) prior to screening is not allowed.
- Pulmonary hypertension that is clinically relevant or severe as deemed by the investigator, or other clinically significant pulmonary abnormalities.
- Unstable cardiovascular or other disease within 6 months prior to the screening visit or during the screening period.
- Presence of other clinically significant airway disease that may, in the opinion of the investigator, impact the study safety or efficacy objectives, such as asthma, bronchiectasis, cystic fibrosis, active aspergillosis, active tuberculosis, or other serious concomitant respiratory disorder other than pulmonary fibrosis.
- Acute exacerbation of IPF within 6 months prior to screening visit and/or during the screening period.
- Patients with underlying chronic liver disease (Child Pugh A, B, or C hepatic impairment), hepatic steatosis (including non-alcoholic steatohepatitis and/or other types of fatty liver diseases).
- Patients with Gilbert's disease
- Relevant chronic or acute infections including human immunodeficiency virus (HIV) and clinically significant viral hepatitis.
- Aspartate aminotransferase or alanine aminotransferase ≥1.5 × upper limit of normal (ULN), and/or total bilirubin ≥1.5 × ULN, and/or gamma glutamyl transferase ≥3 × ULN, and/or alkaline phosphatase ≥1.5 × ULN at screening.
- Estimated glomerular filtration rate <60 mL/min/1.73m2 at screening.
- Patient with 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF) >450 ms for males and >470 ms for females at screening (Visit 1).
- Patient with a history of lung volume reduction surgery or lung transplant.
- Current smoker and/or cotinine (smoking) test positive.
- History of drug abuse, drug use, or alcohol abuse within the past 3 months.
- Major surgery performed within 3 months prior to screening visit, during the screening period, or have major surgery planned during the study period.
- Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening visit.
- Use of any of the following therapies within 4 weeks prior to screening visit and during the screening period or planned during the study: warfarin and immunosuppressive medications.
- Patients currently taking endothelin receptor antagonists,phosphodiesterase type 5 inhibitors, soluble guanylate cyclase modulators, prostacyclin analogues and prostanoids, or activin signaling inhibitor.
- Patients currently on a treatment with nerandomilast within 8 weeks prior to screening visit and during the screening period.
Use of any of the following drugs within 2 weeks prior to Visit 1/screening or planned during the duration of the study
- Strong and moderate cytochrome P450 3A4 or 1A2 inhibitors/inducers
- Medications associated with substantial risk for prolongation of corrected QT interval.
- Patients who have consumed grapefruit or grapefruit juice, pomelo, Seville orange or Seville orange-containing products within 48 hours before Day 1.
- Patients who used hormone replacement therapy in the 4 weeks prior to randomization. No hormone replacement therapy use is allowed during the study.
- Patients with known hypersensitivity or contraindications to serine/threonine kinase inhibitors.
- Any condition that would interfere with the interpretation of study assessments or impair study participation.
- Any physical or psychological conditions or circumstance that, in the opinion of the investigator, may make a patient unsuitable for inclusion or unlikely or unable to complete the study or comply with study procedures and requirements.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Active
Patients assigned will receive ISN018_055 tablets orally QD for 52 weeks
|
Dosage form: Tablets; Frequency of administration: Orally QD.
Other Names: Rentosertib
|
|
Placebo-vergelijker: Placebo
Patients assigned will receive matching placebo orally QD for 52 weeks
|
Dosage Form: Tablet; Frequentie van toediening: Oraal QD.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
the annual rate of forced vital capacity (FVC; mL) decline over 52 weeks.
Tijdsspanne: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
time to first occurrence of any disease progression
Tijdsspanne: up to 52 weeks
|
including 1) percent predicted forced vital capacity decrease relative to baseline greater than 10%, 2) acute exacerbation of IPF, 3) respiratory-related hospitalization, or 4) death due to respiratory
|
up to 52 weeks
|
|
change from baseline to Week 52 in quantitative computed tomography-derived lung fibrosis burden on high-resolution computed tomography(HRCT)
Tijdsspanne: week 52
|
week 52
|
|
|
change from baseline in quality of life (QoL) as measured by the patient-reported outcomes questionnaires using King's Brief Interstitial Lung Disease questionnaire (K BILD)
Tijdsspanne: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in QoL as measured by the patient-reported outcomes questionnaires using Living with Pulmonary Fibrosis(L-PF)
Tijdsspanne: Weeks 0,4,12,26,39,52
|
Weeks 0,4,12,26,39,52
|
|
|
change from baseline in hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) over 52 weeks
Tijdsspanne: Weeks 0, 52
|
Weeks 0, 52
|
Andere uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Incidence of treatment-emergent adverse events(Safety and Tolerability), and clinically significant changes in physical examination,vital signs,safety laboratory test
Tijdsspanne: up to 56 weeks
|
up to 56 weeks
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG QTcF Interval
Tijdsspanne: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
Clinically significant changes in the 12-lead electrocardiogram(ECG) of ECG Heart Rate
Tijdsspanne: Weeks 0,2,4,8,12,26,39,52
|
Weeks 0,2,4,8,12,26,39,52
|
|
changes from baseline in serum proteome by high throughput proteomic analysis at Weeks 12, 26, and 52
Tijdsspanne: weeks 0, 12 ,26, and 52
|
weeks 0, 12 ,26, and 52
|
|
changes from baseline in serum bone biomarker of procollagen 1 intact N-terminal propeptide [P1NP]
Tijdsspanne: weeks 0, 52
|
weeks 0, 52
|
|
changes from baseline in serum bone biomarker of C-terminal telopeptide [CTX]
Tijdsspanne: weeks 0, 52
|
weeks 0, 52
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- INS018-055-301
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .